CTOs on the Move

Samumed

www.samumed.com

 
Samumed is a leader in medical research and development for tissue-level regeneration. With our platform`s origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Samumed raised $438M on 08/06/2018

Similar Companies

CTI BioPharma

CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.

BlueSphere Bio

Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…

GTC Biotherapeutics

GTC Biotherapeutics is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revibe Technologies

Revibe Technologies is dedicated to helping children and adults overcome obstacles faced in the classroom and workplace by fusing psychology with technology. School psychologist Rich Brancaccio founded Revibe in 2013 to create a specialized tool to help kids overcome their difficulties by leveling the playing field through technology. Revibe is a wearable that leverages proprietary algorithms to help kids adults combat distraction through gentle vibration reminders.

Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.